×
About 233 results

ALLMedicine™ Sezary Syndrome Center

Research & Reviews  74 results

Extracorporeal Photopheresis in Sezary Syndrome
https://clinicaltrials.gov/ct2/show/NCT05157581

May 12th, 2022 - Cutaneous T-cell lymphoma (CTCL) is a group of skin lymphomas in which malignant lymphocytes infiltrate the skin and, in the later stages, spread to the lymph nodes and blood (leukemia). In the early stages, CTCL generally has a slow course, but i...

Genetically driven CD39 expression affects Sezary cell viability, IL-2 production and d...
https://doi.org/10.1016/j.jid.2022.04.017
The Journal of Investigative Dermatology; Picozza M, Cristofoletti C et. al.

May 10th, 2022 - Sezary Syndrome (SS) is a rare and aggressive variant of Cutaneous T-Cell Lymphoma. It is characterized by the co-presence of CD4+ neoplastic lymphocytes, named Sezary cells, mainly in the blood, lymph-nodes and skin where they induce chronic infl...

PD-1 improves accurate detection of Sezary cells by flow cytometry in peripheral blood ...
https://doi.org/10.1002/cyto.b.22070
Cytometry. Part B, Clinical Cytometry; Lewis NE, Gao Q et. al.

Apr 23rd, 2022 - Accurate Sezary cell detection in peripheral blood of mycosis fungoides/Sezary syndrome (MF/SS) patients by flow cytometry can be difficult due to overlapping immunophenotypes with normal T cells using standard markers. We assessed the utility of ...

Continuous low-dose gemcitabine in primary cutaneous T cell lymphoma: A retrospective s...
https://doi.org/10.1111/dth.15482
Dermatologic Therapy; Di Raimondo C, Vaccarini S et. al.

Apr 5th, 2022 - The aim of our retrospective study was to evaluate the efficacy of a continuous therapy with a lower dosage of gemcitabine compared to those usually administered in patients with cutaneous T cell lymphomas (CTCL). Twenty-two patients received diff...

Allogeneic hematopoietic stem cell transplantation for heavily pretreated patients with...
https://doi.org/10.1111/dth.15447
Dermatologic Therapy; Cengiz Seval G, Sahin U et. al.

Mar 16th, 2022 - Allogeneic hematopoietic stem cell transplantation (AHSCT) is a promising strategy for treatment of heavily pretreated mycosis fungoides/Sezary syndrome (MF/SS). Herein, we aimed to evaluate the outcomes of AHSCT for heavily pretreated patients wi...

see more →

Clinicaltrials.gov  11 results

Extracorporeal Photopheresis in Sezary Syndrome
https://clinicaltrials.gov/ct2/show/NCT05157581

May 12th, 2022 - Cutaneous T-cell lymphoma (CTCL) is a group of skin lymphomas in which malignant lymphocytes infiltrate the skin and, in the later stages, spread to the lymph nodes and blood (leukemia). In the early stages, CTCL generally has a slow course, but i...

ID Of Prognostic Factors In Mycosis Fungoides/Sezary Syndrome
https://clinicaltrials.gov/ct2/show/NCT02848274

Jun 11th, 2021 - The purpose of the study is to develop a prognostic index model for the rare disease of mycosis fungoides and sezary syndrome. This will be done by collecting standardized clinical data at various institutions. The investigators hope this will ena...

PARCT: Trial of Atezolizumab in Relapsed/Refractory Cutaneous T Cell Lymphoma (CTCL)
https://clinicaltrials.gov/ct2/show/NCT03357224

Jul 31st, 2020 - Trial assessing atezolizumab (anti-PD-L1) as treatment option for patients with mycosis fungoides/sezary syndrome having progressed under or after previous therapy For this study, we invite patients suffering from mycosis fungoides and Sézary synd...

Stem Cell Transplant Therapy With Campath-1H for Treating Advanced Mycosis Fungoides and Sezary Syndrome
https://clinicaltrials.gov/ct2/show/NCT00047060

Mar 10th, 2020 - Primary cutaneous T-cell lymphomas (CTCL) are a group of lymphoproliferative disorders characterized by localization of neoplastic T cells to the skin at presentation. Mycosis fungoides (MF) and its leukemic variant Sezary syndrome (SS) are the mo...

Depsipeptide to Treat Patients With Cutaneous T-Cell Lymphoma and Peripheral T-Cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT00007345

May 16th, 2017 - Background: NSC630176 is a depsipeptide fermentation product from Chromobacterium violaceum with potent cytotoxic activity against human tumor cell lines and in vivo efficacy against both human tumor xenografts and murine tumors (1-3). NSC 630176,...

see more →

News  6 results

FDA Grants Orphan Drug Designation to CFT7455 for Multiple Myeloma
https://www.onclive.com/view/fda-grants-orphan-drug-designation-to-cft7455-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to CFT7455, a MonoDAC degrader targeting IKZF1/3, for use as a potential therapeutic option in patients with multiple myeloma, according to an announcement from C4 Therapeutics, Inc.1 We are pleased ...

Dr. Ai on Potential With Mogamulizumab in CTCL
https://www.onclive.com/view/dr-ai-on-potential-with-mogamulizumab-in-ctcl

Dec 20th, 2020 - Weiyun Z. Ai, MD, PhD, assistant clinical professor, Department of Medicine, University of California San Francisco, speaks to the relevance of mogamulizumab (Poteligeo) in treating Sezary syndrome, a rare and aggressive form of cutaneous T-cell l...

NCCN Guidelines Reflect Recent FDA Approvals for Hematologic Malignancies
https://www.onclive.com/view/nccn-guidelines-reflect-recent-fda-approvals-for-hematologic-malignancies

Dec 5th, 2020 - Meletios A. Dimopoulos, MD New options for patients with hematologic malignancies stemming from recent FDA approvals are making an impact on treatment strategies recommended in the National Comprehensive Cancer Network (NCCN) Clinical Practice Gu...

50th Annual Meeting of the American Society of Hematology
https://www.onclive.com/view/on_2008ash_coverage

Dec 5th, 2020 - The American Society of Hematology held its 50th Annual Meeting in San Francisco in December, hosting more than 21,000 hematologists, clinicians, and scientists from around the world. This grand forum presented a superb educational program, cuttin...

Mogamulizumab Significantly Boosts Outcomes in CTCL With Blood Involvement
https://www.onclive.com/view/mogamulizumab-significantly-boosts-outcomes-in-ctcl-with-blood-involvement

Oct 13th, 2020 - Higher levels of blood tumor involvement were linked with more favorable outcomes in patients who received treatment with mogamulizumab (Poteligeo) compared with vorinostat (Zolinza) in patients with 2 types of cutaneous T-cell lymphoma (CTCL): my...

see more →

Patient Education  2 results see all →